

(FINAL/APPROVED)

## VIRGINIA BOARD OF PHARMACY

### PUBLIC HEARING FOR SCHEDULING CERTAIN CHEMICALS IN SCHEDULE I AND SCHEDULING/DE-SCHEDULING TO CONFORM TO FEDERAL ACTIONS

June 21, 2018  
Second Floor  
Board Room 2

Perimeter Center  
9960 Mayland Drive  
Henrico, Virginia 23233-1463

- CALL TO ORDER: The public hearing was called to order at 9:10a.m.
- PRESIDING: Jodi H. Allen
- MEMBERS PRESENT: Melvin L. Boone, Sr.  
Cheryl H. Nelson  
Rafael Saenz  
Cynthia Warriner  
Sheila K. W. Elliott
- MEMBERS ABSENT: Ryan K. Logan, Chairman  
Michael Elliott, Vice Chairman  
James L. Jenkins, Jr.  
Rebecca Thornbury
- STAFF PRESENT: Caroline D. Juran, Executive Director  
J. Samuel Johnson, Jr., Deputy Executive Director  
Ellen Shinaberry, Deputy Executive Director  
David E. Brown, D.C., Director for DHP  
Barbara Allyson-Bryan, Chief Deputy Director for DHP  
James Rutkowski, Assistant Attorney General
- CALL FOR PUBLIC COMMENT: Ms. Allen called for comment to consider placement of the following chemical substances, identified by the Department of Forensic Science, into Schedule I:
- 2,5-dimethoxy-4-chloroamphetamine (other name: DOC)
  - N-(2-fluorophenyl)-2-methoxy-N-[1-(2-phenylethyl)-4-piperidinyl]-acetamine (other name: Ocfentanil)
  - N-(4-methoxyphenyl)-N-[1-(2-phenylethyl)-4-piperidinyl]-butanamide (other name: 4-methoxybutyrylfentanyl)
  - N-phenyl-2-methyl-N-[1-(2-phenylethyl)-4-piperidinyl]-propanamide (other name: isobutyryl fentanyl)
  - N-phenyl-N-[1-(2-pehnylethyl)-4-piperidinyl]-cyclopentanecarboxamide (other name: Cyclopentyl fentanyl)
  - N-phenyl-N-(1-methyl-4-piperidinyl)-propanamide (other name: N-methyl norfentanyl)
  - 1-(4-cyanobutyl)-N-(1-methyl-1-phenylethyl)-1H-indazole-

3-carboxamide(other name: 4-cyano CUMYL-BUTINACA)

- Flualprazolam

Additionally, Ms. Allen noted that to conform the Drug Control Act to recent scheduling changes enacted by the Drug Enforcement Administration, the Board will consider:

- Adding MT-45 (1-cyclohexyl-4-(1,2-diphenylethyl)piperazine) to Schedule I;
- Adding Dronabinol [(-)-delta-9-*trans* tetrahydrocannabinol] in an oral solution in a drug product approved for marketing by the U.S. Food and Drug Administration to Schedule II; and
- Removing naldemedine from Schedule II.


If approved by the Board of Pharmacy, the placement of these substances in the Virginia Drug Control Act shall go into effect 30 days following publication of the proposed regulation. The scheduling action for the substances identified by the Department of Forensic Science pursuant to §54.1-3443(D) would remain in effect for a period of 18 months. The chemicals would then be de-scheduled unless a general law is passed by the General Assembly placing the chemicals into Schedule I. The scheduling action of the drugs to conform the Drug Control Act to recent scheduling changes enacted by the Drug Enforcement Administration pursuant to §54.1-3443(E) would remain in effect permanently, unless otherwise amended.


PUBLIC COMMENT:

M. Scott Maye, Chemical Program Manager at the Department of Forensic Science provided information regarding the 8 chemicals it has identified for the Board's consideration to place into Schedule I. One chemical is a research chemical, five chemicals are powerful synthetic opioids, one compound is a cannabimimetic agent, and one is a benzodiazepine that has no accepted medical use in the United States.

ADJOURN:

The public hearing adjourned at 9:13am.

  
\_\_\_\_\_  
Jodi H. Allen, Presiding  
  
9/25/18  
\_\_\_\_\_  
Date

  
\_\_\_\_\_  
Caroline D. Juran, Executive Director  
  
9/25/18  
\_\_\_\_\_  
Date